GlaxoSmithKline China Investment introduced Allergan-developed Botox into China in October 2006 as a drug for one-sided facial muscle spasms and eyelid twitching. However, the popular wrinkle-removing Botox injection has yet to receive China's State FDA approval for treatment of glabellar lines between eyebrows. GSK officials say Botox for removing glabellar lines is still in clinical trials, but declined to comment on the progress or expected market prospects for the drug in China. On the other hand, botulinum toxin type A produced by local firm Lanzhou Institute of Biological Products has captured the China market. Although it has not been approved for glabellar lines removal, the drug has gained widespread cosmetic use in many domestic plastics institutions. (Click here for more - Chinese Language)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback
Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
